Alfacell to Host Fiscal Third Quarter 2008 Financial Results Conference Call and Webcast
Released: 06/04/08 08:30 AM EDT

SOMERSET, N.J., June 4 /PRNewswire-FirstCall/ -- Alfacell Corporation (NASDAQ:ACEL) today announced that it will host a conference call and Webcast at 11 a.m. EDT on Monday, June 9. During the call, Lawrence A. Kenyon, Alfacell's president and chief financial officer, will present an overview of Alfacell's financial performance for the fiscal third quarter ended April 30, 2008.

To participate in the live conference call, U.S. residents may dial 1-877-407-9205, and international callers may dial 1-201-689-8054. A replay of the call will be available until June 16. To access the replay, U.S. residents may dial 1-877-660-6853, and international callers may dial 1-201-612-7415 and enter account number 286 and conference ID number 287301. A live Webcast and replay of the conference call will be available on Alfacell's Web site at www.alfacell.com.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to a recently completed Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

    Media Contact:                     Investor Contact:
    David Schull or Wendy Lau          Andreas Marathovouniotis
    Russo Partners                     Russo Partners
    212-845-4271                       212-845-4235
    david.schull@russopartnersllc.com  Andreas.Marathis@russopartnersllc.com
    wendy.lau@russopartnersllc.com

Source: Alfacell Corporation